|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
18
|
|
pubmed:dateCreated |
2000-11-6
|
|
pubmed:abstractText |
Vascular remodeling occurs in the skeletal muscle of patients with severe congestive heart failure (CHF); this remodeling is mediated in part by increased activity of the renin-angiotensin system. Animal models suggest that in the vasculature, angiotensin II receptor type 2 (AT2-R) expression may be upregulated in pathological states associated with vascular remodeling. The therapeutic effects of an AT1-R antagonist may, therefore, be in part due to increased plasma angiotensin II levels, which stimulate AT2-R. However, whether AT2-R is expressed in the skeletal muscle vasculature of patients with severe CHF is unknown.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin Receptor Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin-Converting Enzyme...,
http://linkedlifedata.com/resource/pubmed/chemical/Glyceraldehyde-3-Phosphate...,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Angiotensin, Type 1,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Angiotensin, Type 2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Angiotensin,
http://linkedlifedata.com/resource/pubmed/chemical/von Willebrand Factor
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1524-4539
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
31
|
|
pubmed:volume |
102
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2210-3
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:11056094-Angiotensin Receptor Antagonists,
pubmed-meshheading:11056094-Angiotensin-Converting Enzyme Inhibitors,
pubmed-meshheading:11056094-Biopsy,
pubmed-meshheading:11056094-Blood Vessels,
pubmed-meshheading:11056094-Female,
pubmed-meshheading:11056094-Fetus,
pubmed-meshheading:11056094-Glyceraldehyde-3-Phosphate Dehydrogenases,
pubmed-meshheading:11056094-Heart Failure,
pubmed-meshheading:11056094-Humans,
pubmed-meshheading:11056094-Male,
pubmed-meshheading:11056094-Middle Aged,
pubmed-meshheading:11056094-Muscle, Skeletal,
pubmed-meshheading:11056094-RNA, Messenger,
pubmed-meshheading:11056094-Receptor, Angiotensin, Type 1,
pubmed-meshheading:11056094-Receptor, Angiotensin, Type 2,
pubmed-meshheading:11056094-Receptors, Angiotensin,
pubmed-meshheading:11056094-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:11056094-Sensitivity and Specificity,
pubmed-meshheading:11056094-Severity of Illness Index,
pubmed-meshheading:11056094-von Willebrand Factor
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Angiotensin II receptor subtypes in the skeletal muscle vasculature of patients with severe congestive heart failure.
|
|
pubmed:affiliation |
Department of Medicine, Division of Cardiology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial
|
